Clincosm LogoSign in Get a demo

Diffuse Large B Cell Lymphoma

Showing NaN - NaN of 10
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

Frontline of ASCT in High-risk DLBCL

Recruiting
  • Diffuse Large B Cell Lymphoma
    • Beijing, Beijing, China
      Peking University People's Hospital
    Apr 26, 2023

    Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +3 more
    • Low-Dose Decitabine plus anti-PD-1
    • Beijing, Beijing, China
      ChinaPLAGH
    Apr 18, 2023

    Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma Trial in Hefei, Nanjing, Beijing (LUCAR-20S CAR-T

    Terminated
    • Diffuse Large B Cell Lymphoma
    • +3 more
    • LUCAR-20S CAR-T cells
    • Hefei, Anhui, China
    • +2 more
    Dec 17, 2021

    Diffuse Large B Cell Lymphoma, CNS Lymphoma Trial in Beijing (Methotrexate)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Central Nervous System Lymphoma
    • Beijing, Beijing, China
      Peking union medical college hospital
    Sep 21, 2021

    Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma Trial in Hefei, Nanjing, Beijing (LUCAR-20S CAR-T

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +3 more
    • LUCAR-20S CAR-T cells
    • Beijing, Beijing, China
      Beijing Boren Hospital
    Aug 5, 2021

    Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in China (CD19-targeted Chimeric Antigen

    Recruiting
    • Lymphoma, Non-Hodgkin
    • +2 more
    • CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
    • Beijing, Beijing, China
    • +9 more
    Jan 17, 2021

    Diffuse Large B Cell Lymphoma Trial in Beijing

    Enrolling by invitation
    • Diffuse Large B Cell Lymphoma
      • Beijing, China
        Cancer Institute/Hospital, Chinese Academy of Medical Sciences &
      Jul 25, 2020

      Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom's Macroglobulinemia Trial in

      Unknown status
      • Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
      • +5 more
      • Beijing, Beijing, China
        Cancer Hospital of Chinese Academy of Medical Sciences
      Jul 18, 2017

      Diffuse Large B Cell Lymphoma Trial in Beijing (SCT400 plus CHOP, Rituximab plus CHOP)

      Unknown status
      • Diffuse Large B Cell Lymphoma
      • SCT400 plus CHOP
      • Rituximab plus CHOP
      • Beijing, Beijing, China
        Cancer Hospital Chinese Academy of Medical Sciences
      May 11, 2016